A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Teriflunomide (Aubagio)

indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

First FDA approval2013-05-01
Generic availableYes · 13 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$319.2M in CY2024 Part D spend109K claims · 18K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.544/unit
18 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.591
Across all dosage forms in distribution.
Highest NADAC
$0.637
Range is tight.
Plans with PA
210 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Teriflunomide used for?

indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Is there a generic for Teriflunomide?

Yes. 26 ANDAs filed at FDA, 13 generic manufacturers currently shipping.

How much does my plan pay for Teriflunomide?

Across 329 Part D plans, Teriflunomide averages $0.591/unit (NADAC). Lowest available: $0.544/unit. Highest in distribution: $0.637/unit.

Is Teriflunomide on the FDA shortage list?

No. Teriflunomide is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (18 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.